** Shares of drugmaker ImmunityBio IBRX.O rise 11.1% to $2.3
** Co posts Q1 revenue of $16.5 million, beating analysts' average estimate of $16.02 million, according to data compiled by LSEG
** IBRX reports Q1 net loss of 15 cents/share vs analysts' est of 13 cents/share
** Including session's moves, IBRX stock down 10.7% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。